Work

FIGURE 3 from Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer

Year: 2023

Type: other

Abstract: Immune function pathway scores in 2 R (A and B) and 2 NR (C and D) patients are plotted to show how they vary across time during p53MVA/pembolizumab treatment. Lines show each pathway's score of its weighted mRNA expression levels data derived from the NanoString nCounter PanCancer Immune Profiling Panel analysis. Fluctuating changes in T cell and associated immune function categories are observed in 2 R but not in 2 NR patients.

DOI: 10.1158/2767-9764.24877840

Authors: Ferdynand J. Kos, Paul Frankel, Mihaela Cristea, Melissa Eng, Raechelle Tinsley, Shannon Dempsey, Nora Ruel, Daphne Stewart, Thanh H. Dellinger, Don J. Diamond

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4390013836

Cites:

Cited by:

Related to: 10